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Accepted 19 April 2008The objective of this study was to identify differentially expressed proteins in saliva from
HNSCC patients compared to a control group. Saliva samples from eight individuals with
non-malignant conditions of the head and neck region were employed as a control group
and compared to saliva from eight patients with HNSCC using 2D DIGE analysis and
subsequent mass spectrometry identification of candidate proteins. Beta fibrin (+2.77-fold),
S100 calcium binding protein (+5.35-fold), transferrin (+3.37-fold), immunoglobulin heavy
chain constant region gamma (+3.28) and cofilin-1 (+6.42) were all found to be significantly
increased in the saliva from HNSCC samples compared to the control group whereas
transthyretin (−2.92-fold) was significantly decreased. The increased abundance of one of
the proteins identified (S100 calcium binding protein) was confirmed by immunoblot
analysis. Many of these proteins are involved in tumour progression, metastasis and
angiogenesis. The proximity of saliva to the developing tumour is undoubtedly a major
factor in facilitating detection of these proteins and such a strategy may lead to the
development of a panel of biomarkers useful for therapeutic monitoring and for early
detection of HNSCC.






The development of new proteomic diagnostics remains
critical for the early detection and monitoring of head and
neck squamous cell carcinoma. Ninety five percent of cancers
arising from the mucosa of the upper aerodigestive tract,
including the oral cavity, larynx, pharynx, nose and paranasal
sinuses, are squamous cell carcinomas [1]. Head and neck
squamous cell carcinoma (HNSCC) is an aggressive epithelial
malignancy in which the early diagnosis of premalignantr Cellular Biotechnology,
wling).
er B.V. All rights reservedlesions is known to directly correlate with increased survival.
Patients often present with advanced stage disease and
despite combined therapy outcome remains poor. The major
risk factors for head and neck cancer are chronic exposure of
epithelia to tobacco smoke or alcohol, infection with the
human papilloma virus types 16 and 18 (HPV) and genetic
susceptibility [2].
Human tissue and biological fluids contain many proteins
and small molecules which have the potential to be used as
biomarkers [3]. Most research into cancer biomarkers hasDublin City University, Glasnevin, Dublin 9, Ireland. Tel.: +353 1
.
Table 1 – Clinical information for the control and HNSCC
groups used in this study
Sex Age Diagnosis Smoker
Control group
F 66 MNG No
M 47 Otitis externa Yes
M 61 Sinusitis Yes
M 39 Cholesteatoma Yes
F 69 SNHL No
M 25 Apthous mouth ulcers No
M 49 Cholesteatoma Yes
M 59 External exostosis EAC Yes
HNSCC group
F 48 Max Sinus SCC Yes
M 71 Oesophageal SCC Yes
M 66 Hypoparyngeal SCC Yes
M 48 Pyriform Fossa SCC Yes
M 56 Suprglottic SCC No
M 81 VC SCC Yes
M 71 Hypopharyngeal SCC No
M 72 R vocal cord SCC Yes
The control group consisted of 8 patients with non-cancerous
tumours/conditions of the head and neck region. The mean age of
the groupwas 51.88 years with a standard deviation of ±13.91 years.
MNG: multinodular goiter, SNHL: sensorineural hearing loss, EAC:
external auditory canal. The HNSCC group consisted of 8 patients.
The mean age of the group was 64.13 years with a standard
deviation of ±11.35 years.
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urine. Saliva, on the other hand, has been relatively poorly
investigated as a source of biomarkers. The proximity to both
premalignant and malignant head and neck neoplasms of
saliva means it offers great potential for their detection [4]. A
saliva-based diagnostic approach would be extremely advan-
tageous because of its relatively non-invasive approach and
with the developments in proteomic technology, identifica-
tion of such diagnostic markers for early detection and
prognostic markers for disease recurrence and treatment
sensitivities employing saliva-based diagnostic tests are
certainly attainable [5,6].
Analysis of the saliva proteome also presents many
challenges. Similar to other biofluids such as serum, saliva
displays a wide dynamic range with abundant proteins such
as amylase and proline-rich proteins masking the presence of
lower abundant proteins that are more likely to be of
importance from a biomarker discovery point of view [6].
Specific saliva targeted immunodepletion columns regularly
used in serum or plasma studies for the depletion of abundant
proteins like albumin are not yet available for processing
saliva [7]. The saliva proteome is a particularly hostile
environment with proteins subjected to the affects of many
host- and bacteria-derived enzymes, resulting in the genera-
tion of many modified proteins making analysis more
complex [8]. However, recent developments in proteomics,
especially in mass spectrometry and new labelling technolo-
gies will undoubtedly help in the successful analysis of the
saliva proteome.
In order to examine differences in saliva protein levels
associated with HNSCC, a proteomics based approach was
initiated involving 2D DIGE analysis and subsequent mass
spectrometry to generate a panel of biomarkers found to be
differentially expressed between the cancerous and non-
cancerous samples.2. Materials and methods
2.1. Chemicals
Iodoacetamide (IAA), DTT, CHAPS, urea, thiourea, glycerol,
30% acrylamide-N,N,N bisacrylamide SDS, TEMED, ammo-
nium persulfate, and glycine were acquired from Sigma-
Aldrich (St. Louis, MO, USA). IPGs pH 3–11 NL, pharmalyte 3–
11 NL, DIGE reagents and dry strip cover fluid were purchased
from GE Healthcare (Uppsala, Sweden).
2.2. Clinical specimens
All 16 patients were treated at the Royal Victoria Eye and Ear
Hospital, Dublin, between 2006 and 2007 and approval to
conduct this study was granted by the Royal Victoria Eye and
Ear Hospital Ethics Committee. The control group consisted of
8 patients with non-cancerous tumours/conditions of the
head and neck region. The mean age of the group was
51.88 years with a standard deviation of ±13.91 years
(Table 1). Using a control group with inflammatory non-
malignant conditions of the head and neck allows for a greater
chance that any protein identified with a difference inabundance levels between the cancer and control groups is a
tumour specific protein and not associated with the inflam-
matory/immune response. The HNSCC group consisted of 8
patients. The mean age of the group was 64.13 years with a
standard deviation of ±11.35 years (Table 1).
2.3. Sample collection and preparation
Unstimulated whole saliva samples were collected in the
morning. All the subjects were asked to be on an empty
stomach, without having had any drink or eaten any kind of
food since the night before. In order tominimize degradation
of the proteins, the sampleswere processed immediately and
kept on ice during the process. Between 1 and 4 mL of saliva
was obtained from each subject with protease inhibitory
cocktails (PICs) added immediately. To remove debris and
cells, the salivawas centrifuged at 14,000 ×g for 15min at 4 °C.
Proteins from the resulting supernatants were concentrated
using 5 kDa Amicons (Millipore) by centrifugation at 4000 ×g
for 45 min at 4 °C. 200 µl of the resulting retenate was treated
using the ReadyPrep 2-D cleanup kit (Bio-Rad) to precipitate
the protein and remove agents that interfere with IEF. PICs
was added to all buffers used in the ReadyPrep 2-D cleanup
kit. The isolated saliva proteins were resuspended in buffer
containing (4% (w/v) CHAPS, 7 M urea, 2 M Thiourea, 10 mM
Tris–HCl, 5 mM Magnesium Acetate pH 8.5). Insoluble
material was removed by centrifugation at 14,000 ×g for
10 min at 4 °C. The protein amount was estimated using an
RC DC protein assay from Bio-Rad. BSA was used as a
standard.
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Saliva were labelled with N-hydroxy succinimidyl ester-
derivatives of the cyanine dyes Cy2, Cy3, and Cy5 following
the protocol described previously [9]. Typically, 50 µg of
protein was minimally labelled with 200 pmol of either Cy3
or Cy5 for comparison on the same 2D gel. Labelling reactions
were performed on ice in the dark for 30 min and then
quenched with a 50-fold molar excess of free lysine to dye for
10 min on ice. A pool of all samples was also prepared and
labelled with Cy2 to be used as a standard on all gels to aid
imagematching and cross-gel statistical analysis. The Cy3 and
Cy5 labelling reactions (50 µg of each) from each lysate were
mixed and run on the same gels with an equal amount (50 µg)
of Cy2-labeled standard [10].
2.5. Protein separation by 2D gel electrophoresis and gel
imaging
Immobilized 24 cm linear pH gradient (IPG) strips, pH 3–11,
were rehydrated in rehydration buffer (7 M urea, 2 M Thiourea,
4% CHAPS, 0.5% IPG Buffer, 50 mM DTT) overnight, according
to the manufacturer's guidelines. Isoelectric focusing was
performed using an IPGphor apparatus (GE Healthcare) for a
total of 40 kV/h at 20 °C, 50 mA. Strips were equilibrated for
20 min in 50 mM Tris–HCl, pH 8.8, 6 M urea, 30% (v/v) glycerol,
1% (w/v) SDS containing 65mMDTT and then for 20min in the
same buffer containing 240 mM iodoacetamide. Equilibrated
IPG strips were transferred onto 18×20-cm 12.5% uniform
polyacrylamide gels poured between low fluorescence glass
plates. Strips were overlaid with 0.5% (w/v) low melting point
agarose in running buffer containing bromphenol blue. Gels
were run using the Ettan Dalt 12 apparatus (GE Healthcare) at
2.5 W/gel for 30 min then 100 W in total at 10 °C until the dye
front had run off the bottom of the gels. All the images were
collected on a Typhoon 9400 Variable Mode Imager (GE
Healthcare). Statistics and quantitation of protein expression
were carried out in Decyder software (GE Healthcare).
2.6. Spot digestion and LC–MS analysis
Preparative gels containing 300 µg of protein were fixed in 30%
(v/v) methanol, 7.5% (v/v) acetic acid overnight and washed in
water, and total protein was detected by post-staining with
SyproRuby dye (Molecular Probes) for 3 h at room temperature
or Colloidal Coomassie (Sigma) for 2 h at room temperature.
SyproRuby stained gels were imaged using a Typhoon 9400
Variable Mode Imager (GE Healthcare) at the appropriate
excitation and emission wavelengths for the stain. The
subsequent gel image was imported into the BVA module of
DeCyder software and wasmatched to images generated from
DIGE analysis. Spots of interest were selected and confirmed
using this software for subsequent picking using an Ettan Spot
Picker. Individual gel pieces after dehydration were covered in
digestion buffer (12.5 ng trypsin per µl of 10% Acetronitrile
40 mM Ammonium Bicarbonate) to cover the gel pieces.
Exhaustive digestion was carried out overnight at 37 °C. After
digestion, the sampleswere centrifuged at 12,000 ×g for 10min
using a bench top centrifuge. The supernatant was carefully
removed from each sample and placed into clean andsilconized plastic tubes. Samples were stored at −70 °C until
analysed by MS.
Tryptic digested proteinswere analysed by one-dimensional
LC–MS using the Ettan MDLC system (GE Healthcare) in high-
throughput configuration directly connected to a Finnegan LTQ
(Thermo Electron). Samples were concentrated and desalted on
RPC trap columns (Zorbax 300SB C18, 0.3 mm×5 mm, Agilent
Technologies, and the peptides were separated on a nano-RPC
column (Zorbax 300SB C18, 0.075 mm×100 mm, Agilent
Technologies) using a linear acetonitrile gradient from 0% to
65% ACN (Sigma) over 60 min. All buffers used for nano LC
separation contained 0.1% formic acid (Fluka) as the ion pairing
reagent. Full scan mass spectra were recorded in profile mode
and tandemmass spectra in centroid mode. The peptides were
identified using the information in the tandemmass spectra by
searching against the SWISS PROT database using SEQUEST.
2.7. 1-D gel and immunoblot analysis
10 ug of protein was loaded onto a 12% NuPAGE Bis–Tris Gels
(Invitrogen) and electrophoretically separated using a MOS/
SDS buffer according to the manufacturer's instructions.
Electrophoretic transfer of proteins to Hybond-ECL nitrocellu-
lose membranes (GE Healthcare) was carried out using a Bio-
Rad Transblot SD cell (Bio-Rad). Proteins were transferred for
50 min at 0.34 mA. Efficiency of transfer was evaluated using
Ponceau-S-Red staining of nitrocellulose membranes. Mem-
branes were blocked for 1 h in 5% (w/v) fat-freemilk powder in
PBS containing 0.5% Tween-20. Membranes were then incu-
bated overnight at 4 °C with the primary antibody, MRP14
[S100-Calcium binding protein A9] (Abcam ab24111) at a
concentration of 1:1000. Nitrocellulose replicas were subse-
quently washed twice for 10min in blocking solution and then
incubated with corresponding peroxidase-conjugated second-
ary antibody (Abcam ab6728) for 1 h at room temperature at a
concentration of 1:2000. Visualization of immuno-decorated
1D bands was carried out using an enhanced chemilumines-
cence kit (GE Healthcare). Statistical analysis was performed
using ImageQuant TL (GE Healthcare).
2.8. Statistical analysis
Two-sided, Student's t-tests were used to analyze differences
in protein levels between saliva samples from the control
group and saliva from patients with head and neck cancer. A
p-value of less than 0.05 was considered statistically
significant.3. Results
3.1. DIGE analysis of saliva
50 µg of protein from each sample was labelled with Cy2, Cy3,
or Cy5. In total 16 gels were run comprised of 8 gels (8 HNSCC
samples v 8 Control samples) run in duplicate. All sixteen
samples were labelled with Cy3 or Cy5 incorporating dye-
swapping (i.e. reciprocal labelling of Cy3 and Cy5) to eliminate
any dye bias. All 16 samples analysed in the experiment were
used in the Cy2 labelled internal pooled standard. Samples
Fig. 1 – Image of saliva proteins analyzed using two-dimensional polyacrylamide gel electrophoresis (2D DIGE). Proteins were
separated based on their isoelectric point, (3–11 range) and their molecular weight to generate a protein expression map (PEM).
Highlighted are 6 proteins that were found to have significant differences in abundance levels between the samples.
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DeCyder image analysis, the differential in-gel analysis mode
of DeCyder was first used to merge the Cy2, Cy3, and Cy5
images for each gel and to detect spot boundaries for the
calculation of normalized spot volumes/protein abundance.
At this stage, features resulting from non-protein sources,
namely dust particles and scratches, were filtered out. The
analysis was used to rapidly calculate abundance differences
between samples run on the same gel. The biological variation
analysismode of DeCyder was then used tomatch all pairwise
image comparisons from difference in-gel analysis for a
comparative cross-gel statistical analysis. Operator interven-
tion was required at this point to set landmarks on gels for
more accurate cross-gel image superimposition. ComparisonTable 2 – Table of proteins found to have increased or decreased
group
Position on gel Protein ID Protein AC Ave
1 Transthyretin gi|339685|
2 Transferrin gi|37747855|
3 S100 calcium binding protein A9
(calgranulin B)
gi|56205191|
4 Immunoglobulin heavy chain
constant region gamma 2
gi|12054074|
5 Fibrin beta gi|223002|
6 Cofilin 1 (non-muscle) gi|30582531|
Listed are the protein identities obtained by LC–MS analysis, gene indexof normalized Cy3 and Cy5 spot volumes with the correspond-
ing Cy2 standard spot volumes within each gel gave a
standardized abundance. A 2D DIGE combined image of Cy2,
Cy3 and Cy5 labelled saliva proteins from both the control and
HNSCC groups is shown in Fig. 1. Highlighted are 6 proteins
that were found to have significant differences in abundance
levels between the samples. The 6 differentially expressed
proteins included in Table 2 all had a p-value of ≤0.05. Proteins
found to have higher abundance levels in HNSCC saliva
compared to the control group included beta fibrin, S100
calcium binding protein, transferrin, cofilin-1 and immuno-
globulin heavy chain constant region gamma 2. Transthyretin
was found to have a lower abundance level in HNSCC saliva
compared to the control group.abundance levels in HNSCC saliva compared to the control







number, average ratio and matched number of peptides.
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Protein identities were achieved using the Ettan MDLC system
(GE Healthcare) in high-throughput configuration directly
connected to a Finnegan LTQ (Thermo Electron). Fig. 2 shows
a base peak chromatogram (full ms) generated by LC–MS–MS
analysis of the S100 calcium binding protein digest using the
Finnegan LTQ mass spectrometer (Fig. 2A). Also shown is a
continuous b or y-ion series of at least six residues for peptide
DLQNFLK from S100 calcium binding protein A9 (Fig. 2B).
Protein identification was performed using the Turbo-
SEQUEST algorithm in the BioWorks 3.1 software package
(Thermo Electron) and the Swiss-Prot human database (Swiss
Institute of Bioinformatics, Geneva, Switzerland). The identi-
fied peptides were further evaluated using charge state versusFig. 2 – (A) Base peak chromatogram (full ms) generated by LC–MS
the Finnegan LTQmass spectrometer coupled to the GEHealthcar
for peptide KDLQNFLK from S100 calcium binding protein. The cri
singly charged ions, XCorr >2.0 for doubly charged ions, and XCcross-correlation number (XCorr). The criteria for positive
identification of peptides was XCorr N1.5 for singly charged
ions, XCorr N2.0 for doubly charged ions, and XCorr N2.5 for
triply charged ions.
3.3. Western blot analysis
Western blot and statistical analysis of saliva from control and
HNSCC samples was performed using an antibody to MRP14
(S100 calcium binding protein). Western blot analysis was
performed on all 16 samples with the representative figure.
(Fig. 3) showing results for 8 of the individual samples (4
HNSCC samples v's 4 Control samples). The results confirm
the increase in abundance levels of S100 calcium binding
protein in HNSCC samples compared to the control group.–MS analysis of the S100 calcium binding protein digest using
eMDLC. (B) continuous b or y-ion series of at least six residues
teria for positive identification of peptides were XCorr >1.5 for
orr >2.5 for triply charged ions.
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dance levels for S100 calcium binding protein which compares
favourably to the 5.35-fold increase generated using 2D DIGE.
To show visually alterations in corresponding spot intensity
proportions, a 3-D image of S100 calcium binding protein A9 is
shown (Fig. 3). This figure demonstrated the increase in
abundance levels for this protein in saliva samples from
patients with HNSCC compared to the control group. Images
were generated using the Biological variation analysis (BVA)
module of DeCyder software. Due to limited sample amounts,
validation of the 2D DIGE results was performed with only one
protein, S100 calcium binding protein. This supports the
results seen in the 2D DIGE analysis. Future work willFig. 3 –Western blot and statistical analysis of saliva from
control and HNSCC samples using an antibody to MRP14
(S100 calcium binding protein). The results confirm the
increase in abundance levels of S100 calcium binding protein
in HNSCC samples compared to the control group. Western
blot analysis showed a 4.6-fold increase in abundance levels
for S100 calcium binding protein which compares favourably
to the 5.35-fold increase generated using 2D DIGE. This is a
representative blot for analysis on all samples performed in
duplicate. Also displayed is a 3-D image of S100 calcium
binding protein A9. This figure demonstrated the increase in
abundance levels for this protein in saliva samples from
patients with HNSCC compared to the control group. Images
were generated using the BVA module of DeCyder software.
Control saliva: lanes 1–4, HNSCC saliva: lanes 5–8.investigate the expression of the other candidate proteins by
western blot analysis in larger sample sets.4. Discussion
In this study, we quantified the protein levels of saliva
proteins in HNSCC compared to a control group with the
purpose of detecting differences in the levels of proteins
which could serve as markers for the disease. HNSCC is very
difficult to diagnose and often early small lesions can be
missed. As a result, this cancer is usually diagnosed at an
advanced stage. A panel of biomarkers detectable in the saliva
of patients with HNSCC may allow for the development
diagnostics assays for early detection and prognostic markers
for disease recurrence and treatment sensitivities. Many
papers have now been published on analysis of the saliva
proteome investigating disease specific proteins. The p53
antibody can be detected in the saliva of patients diagnosed
with oral squamous cell carcinoma [11] and increased levels of
human alpha-defensin 1 (HNP-1) was found to be indicative of
the presence of oral SCC in a study by Mizukawa et al. [12].
Recently an examination into salivary soluble CD44 (solCD44)
expression in HNSCC patients and normal controls showed
that solCD44 ELISA seems to effectively detect HNSCC at all
stages [13]. Interleukin 8 was detected at higher concentra-
tions in saliva of patients with OSCC (oral cavity and
oropharyngeal squamous cell carcinoma) as measured by
real-time polymerase chain reaction analysis and enzyme-
linked immunosorbent assay [14]. Salivary biomarkers for
other cancers have also been identified. The tumourmarker c-
erbB-2 (erb) was found in the saliva of women diagnosed with
breast carcinoma, as compared with patients with benign
lesions and healthy controls [15], and elevated salivary levels
of CA 125 were detected in patients with malignant ovarian
tumours [16].
The six proteins listed in Table 2 were detected in all 16
samples (8 HNSCC samples and 8 Control samples). Five were
found to have significantly increased abundance levels in the
saliva from the HNSCC samples compared to the control
group, namely beta fibrin (+2.77-fold), S100 calcium binding
protein (+5.35-fold), transferrin (+3.37-fold), immunoglobulin
heavy chain constant region gamma (+3.28) and cofilin-1
(+6.42). Transthyretin (−2.92-fold) was the only proteins found
to be significantly decreased.
The S100 protein family consists of 20 known members and
are likely involved inmany of the aspects of tumourigenesis and
metastasis. Of the 20 knownmembers of the S100 protein family,
only serumlevelsof S100B isusedclinically inmelanomapatients
at all stages of the tumour. S100A9 which forms a heterodimeric
complex with S100A8, is found with increased abundance levels
in gastric and colorectal cancer [17,18]. Yong and Moon recently
demonstrated that by employing small-interfering RNA (siRNA)
targeting S100A8 or S100A9, the invasive and migratory pheno-
types of SNU484 cells were significantly inhibited [17].
Of increased relevance to our study, the recent paper by
Sewell and co-workers [19], identified potential biomarkers of
laryngeal cancer tissue specimens using two-dimensional
differential in-gel electrophoresis andmass spectrometry. The
results of their analysis showed that the expression of a
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specimens when compared to match normal controls, includ-
ing S100 calcium binding protein A9. Melle and co-workers
demonstrated that calgranulin A and calgranulin B were
detectable in protein lysates from positive areas and were
absent in the negative areas of pharyngeal squamous tumour
epithelial cells, using ProteinChip arrays [20]. Driemel and
colleagues showed that S100A8 and S100A9 can differentiate
between normal mucosa, inflammatory and hyperprolifera-
tive lesions, and oral squamous cell carcinoma with a
sensitivity of 100% and specificity of 91% using SELDI-ToF [21].
In our study we found S100A9 to have a 5.35-fold increase
in abundance levels in the saliva from the HNSCC group
compared to the control group using 2D DIGE. This result was
confirmed using Western blot analysis, showing a 4.6-fold
increase in abundance levels for S100A9. S100A8 was also
detected in our study and was found to be of increased
abundance in the saliva from the HNSCC group but was
excluded because the p-value for this protein was outside the
selected value for this study.
This study and previous studies have demonstrated the
importance of S100A9 in HNSCC as a potential biomarker and
with further insight into its function within the tumour
micro-environment itmay be a valid target for new therapies.
Ohshiro and co-workers recently described work on saliva
samples from healthy individuals and HNSCC patients. Their
analysis identified two proteins, α-1-B-glycoprotein and
complement factor B proteins to be present in saliva samples
from HNSCC patients but not in normal specimens. Cystatin
S, parotid secretory factor, and poly-4-hydrolase ß-subunit
proteins were detected in most normal saliva but not in
patient specimens. Interestingly they identified S100 calcium
binding protein A9 in both HNSCC patient saliva and in
normal samples as described in this paper [22].
The presence of fibrin in and around tumoursmay play an
important role in tumour growth [23]. Fibrin could form an
adhesive support for cell anchorage during local expansion
and emigration. Fibrin may also promote angiogenesis. The
fibrin clot and the associated coagulation factors provide a
highly pro-angiogenic environment [24] Previous studies
documented the presence of fibrin and fibrinogen in situ in
small cell carcinoma of the lung, renal cell carcinoma,
malignant melanoma, and ovarian carcinoma [25–31]. In
this study it was found that beta fibrin was 2.77 fold increased
in abundance levels in the saliva from the patients with
HNSCC compared to the control group. Beta fibrin has
important functions in tumour progression and the detection
of this protein in the saliva is significant. The proximity of the
saliva to the developing tumour is fundamental to the
detection of such proteins.
Transferrin, cofilin-1, immunoglobulin heavy chain con-
stant region gamma 2 and transthyretin were also found to
have significant differences in abundance level in HNSCC
saliva compared to the control group. Transthyretin is a
traditional biomarker for nutritional and inflammatory status.
In this study it was found that the levels of transthyretin were
significantly decreased in the saliva from the HNSCC group.
Recently a truncated from of transthyretin was included in a
panel of three proteins in a study on serum biomarker
discovery for ovarian cancer in women [32]. Turhani et al.,recently demonstrated that cofilin was 2.2 fold increased in
abundance levels in fractions enriched in cytosolic and
mitochondrial proteins from oral squamous cell carcinoma
whole tumour samples compared to surroundingmucosa [33].
One of the most important aspects of investigations into
expression-based clinical proteomics is the employment of a
proper control group. Many proteins identified in biomarkers
discovery studies are often found to be acute phase proteins,
and are associated with the inflammatory state resulting from
the disease [34]. In this studywewere able to use controls with
inflammatory non-malignant conditions of the head and neck
therefore allowing a greater chance that any protein identified
with a difference in abundance levels between the cancer and
control groups is a tumour specific protein.
Human saliva is attractive for disease diagnostics because
its collection is less invasive than that of blood for serum/
plasma analyses. Markers found in saliva are likely to be
relatively selective for HNSCC. Many of today's biomarkers are
found associated with multiple cancers making precise
diagnosis difficult. Many proteins that make up the saliva
proteome have now been identified and catalogued, but many
more are still to be discovered. Immunodepletion columns are
now widely available for serum/plasma processing but a
specific column for saliva is not yet available. Ohshiro and
co-workers recently used an immunodepletion column com-
monly used to deplete serum, plasma or CSF of major proteins
in their study on saliva proteins [22]. The results were very
interesting with the removal of abundant proteins like
albumin allowing analysis of lower level proteins. Immuno-
depletion of as many major saliva proteins such as mucins,
amylases and immunoglobulins would allow researchers to
mine deeper into the saliva proteome and analyse protein
fragments and associated peptide that are disease specific. It is
also interesting to note that abundant proteins such as
transferrin and immunoglobulin heavy chain constant region
gamma were found to be of particular interest in this study.
Theuse of depletion columnswould remove these proteins but
it seems reasonable that analysis of the abundant protein
fraction might also uncover some valuable information.
Recent developments in proteomic technologies like mass
spectrometry, liquid chromatography and protein/peptide
labelling technologies will undoubtedly help researchers
detect low abundance molecules in the saliva proteome. The
ultimate goal of a quick cost effective, minimally invasive test
for groups at high risk of developing HNSCC and for the
monitoring of response to specific therapeutic regimes are
certainly achievable.Acknowledgement
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